A pilot study of nedaplatin and etoposide for recurrent gynecological malignancies.
Nedaplatin is a new analogue of cisplatin with similar efficacy but less renal toxicity. We assessed the efficacy and toxicity of nedaplatin and etoposide for recurrent gynecological malignancies. Eight patients were treated with 100 mg/m2 of nedaplatin (day 1) and 70 mg/m2 of etoposide (days 1, 3, and 5 ) every 4 weeks. A total of 17 courses was given. Grade 3/4 leucopenia and thrombocytopenia occurred, but was manageable. The response rate was 37.5% (partial response n=3; no change n=4; progressive disease n=1). In conclusion, a phase II study of this regimen for recurrent gynecological malignancies is warranted.
Adachi
S
S
Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya city, Hyogo 663, Japan.
Ogasawara
T
T
Yamasaki
N
N
Shibahara
H
H
Tsuji
Y
Y
Takemura
T
T
Koyama
K
K
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010865:Pilot Projects; D016896:Treatment Outcome
D009944:Organoplatinum Compounds; D005047:Etoposide; C053989:nedaplatin